<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>FDA-approved clinical trials &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/fda-approved-clinical-trials/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 06 Oct 2025 17:27:34 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>FDA-approved clinical trials &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>FDA Approves UCLA’s Heart Tissue Regeneration Drug AD-NP1 for Clinical Trials</title>
		<link>https://bioengineer.org/fda-approves-uclas-heart-tissue-regeneration-drug-ad-np1-for-clinical-trials/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 06 Oct 2025 17:27:30 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[ENPP1 protein inhibition]]></category>
		<category><![CDATA[FDA-approved clinical trials]]></category>
		<category><![CDATA[Heart tissue regeneration]]></category>
		<category><![CDATA[Monoclonal antibody drug development]]></category>
		<category><![CDATA[UCLA cardiology research]]></category>
		<guid isPermaLink="false">https://bioengineer.org/fda-approves-uclas-heart-tissue-regeneration-drug-ad-np1-for-clinical-trials/</guid>

					<description><![CDATA[In a groundbreaking advancement that could redefine the treatment of organ injury, UCLA cardiologists have unveiled a novel therapeutic approach centered on a protein that has long hindered tissue regeneration in internal organs. While the human body’s capacity for healing is remarkable, the regenerative potential of vital organs like the heart and kidneys remains limited [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">276510</post-id>	</item>
	</channel>
</rss>
